On News of Illumina Bid, Solexa Shares Climb 29 Percent as Illumina's Dive 13 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Solexa were up 29 percent and shares in Illumina were down 13 percent in midday trading after Illumina said this morning it plans to buy Solexa for roughly $600 million in stocks.
 
Solexa was trading up $2.83 a share at $12.51 while Illumina was trading down $5.75 at $38.28.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.